WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search    Hide text from Guidelines

C CARDIOVASCULAR SYSTEM

This group comprises substances used for the treatment of cardiovascular conditions.
Drugs used for the treatment of hypertension are classified in C02 - Antihypertensives, C03 - Diuretics, C07 - Beta blocking agents, C08 - Calcium channel blockers, and C09 - Agents acting on the renin-angiotensin system. For the classification of combination products of antihypertensives from different ATC groups, the following ranking should be used, from higher to lower precedence: C09, C07, C08, , and C03.


C01 CARDIAC THERAPY
C01C CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES

This group comprises agents for the treatment of hypotension. Respiratory stimulants are classified in R07AB.
Dihydroergotamine, which is used in the treatment of migraine as well as hypotension, is classified in N02CA - Ergot alkaloids.
Combinations with peripheral vasodilators, see C04 - Peripheral vasodilators.

This group includes various drugs used on different indications. The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).


C01CA Adrenergic and dopaminergic agents

This group comprises sympathomimetics used in the treatment of hypotension.
Etilefrin in combination with dihydroergotamine is classified in this group.
Oral products of ephedrine are classified in R03CA.

C01CE Phosphodiesterase inhibitors

Phosphodiesterase inhibitors such as theophylline, which are used in asthma therapy, are classified in R03D.

C01CX Other cardiac stimulants

This group includes agents, which cannot be classified in the preceding groups.

Last updated: 2023-01-23